Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar
9.7.2026 15:00:00 CEST | Business Wire | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers.
With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity.
The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The company has begun end-to-end manufacturing operations which will eventually be able to produce more than 30,000 radars annually – equivalent to more than 2,500 radars each month.
Over the coming months, Echodyne will transition all manufacturing operations from its headquarters to the new site, creating a dedicated manufacturing and operations hub capable of supporting sustained production growth across its radar portfolio. The company’s $40 M investment in a state-of-the-art manufacturing facility is complemented by more than 100 new jobs and up to 200 as the facility reaches full production capacity.
“Our global customer base is demanding more radar to be delivered as fast as possible,” said Eben Frankenberg, CEO of Echodyne. “Drones are driving significant change in both enabling a drone economy and in defending against nefarious drone use. While radar performance will always be the dominant consideration, product availability both now and in a predictable and consistent manner over time is quickly becoming a requirement for any global supplier. The only way to defend against mass is with mass. That requires not just high-performance economical radars, but the ability to manufacture them at scale."
Demand for high-performance radar continues to grow across a broad range of applications including counter-UAS, force protection, border security, intelligence, surveillance and reconnaissance, protection of critical infrastructure, and beyond visual line of sight (BVLOS) operations for autonomous systems.
Unlike conventional electronically scanned array radars that rely on thousands of phase shifters, Echodyne's patented Metamaterials Electronically Scanned Array (MESA®) architecture achieves electronic beam steering through a fundamentally simpler design. Manufactured using standard materials and scalable commercial processes, the technology delivers high-fidelity radar performance while reducing the size, weight, power, complexity, and cost traditionally associated with electronically scanned array radar. The result is a compact, software-defined, commercially exportable product designed not only for performance, but for manufacturability at commercial scale.
The new facility provides approximately 74,350 square feet of manufacturing space and 12,000 square feet of warehousing, enabling production to flex across multiple radar product lines while supporting future product introductions.
That same design philosophy extends into manufacturing. Rather than relying on traditional low-volume defense production, Echodyne's manufacturing approach combines breakthrough radar technology with commercially scalable production techniques. The simplicity of the company's MESA architecture was engineered not only to deliver exceptional radar performance, but also to maximize manufacturability, allowing production to scale efficiently using commercial manufacturing methods while maintaining consistent quality. The company's modular approach enables manufacturing capacity to flex across product lines, rapidly introduce new capabilities, and respond quickly to changing customer demand.
Recent program awards and growing international demand underscore the need for expanded manufacturing capacity. Echodyne's radar technology is integrated into hundreds of defense and security systems worldwide and supports platforms developed by leading defense companies including Anduril, Axon, Moog, and Northrop Grumman Corporation.
Most recently, the company was selected as the primary radar provider for Trust Automation's Small UAS Detection System (SUADS) platform, which is being delivered to the U.S. Air Force under a $490 million indefinite-delivery/indefinite-quantity (IDIQ) contract.
The company expects to continue expanding its workforce as manufacturing operations scale.
About Echodyne
Echodyne, the radar platform company, is a U.S. designer and manufacturer of high-performance radar systems for defense, government, and commercial market applications. The company combines patented metamaterials electronically scanned array (MESA®) technology with powerful software and machine learning to deliver high-fidelity situational awareness data pinpointing activity in air and surface domains with unrivalled speed, accuracy, and precision. Proven and trusted by militaries, agencies, integrators, and critical infrastructure around the globe, Echodyne’s products set a new standard for commercial high-fidelity radar excellence. Privately held, the company is headquartered in Kirkland, WA, USA and backed by Bill Gates, NEA, Madrona Venture Group, Baillie Gifford, and Northrop Grumman, among others. See radar in action at Echodyne.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260709136953/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom